BUSINESS● LOW13h ago · Oct 13, 2026, 10:56 AM
Johnson & Johnson in charts: Innovative medicine growth offsets Stelara drag in Q3; U.S. sales rise 9.1% Y/Y
Seeking Alpha Tech · north america
Johnson & Johnson's Q3 performance shows growth in innovative medicines compensated for a decline in Stelara sales, with overall U.S. sales increasing year-over-year. This report provides an update on the company's financial health and product performance.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS20m agoWhy did Hong Kong’s 11 Skies fail and can the megaproject be rescued?South China Morning PostBUSINESS21m agoSingapore third-quarter GDP growth softens from four-year high but beats estimatesCNBC